Balance Sheet
Cash Flow Statement
Capital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Inhibikase Therapeutics (IKT) Cash from Investing Activities (2022 - 2025)

Inhibikase Therapeutics (IKT) has disclosed Cash from Investing Activities for 4 consecutive years, with -$28.7 million as the latest value for Q3 2025.

  • On a quarterly basis, Cash from Investing Activities fell 1237.96% to -$28.7 million in Q3 2025 year-over-year; TTM through Sep 2025 was -$36.6 million, a 10124.16% decrease, with the full-year FY2024 number at -$37.0 million, down 417.45% from a year prior.
  • Cash from Investing Activities was -$28.7 million for Q3 2025 at Inhibikase Therapeutics, down from $9.8 million in the prior quarter.
  • In the past five years, Cash from Investing Activities ranged from a high of $21.1 million in Q1 2025 to a low of -$38.8 million in Q4 2024.
  • A 4-year average of -$2.8 million and a median of $1.2 million in 2022 define the central range for Cash from Investing Activities.
  • Peak YoY movement for Cash from Investing Activities: skyrocketed 6017.7% in 2023, then plummeted 1732.19% in 2024.
  • Inhibikase Therapeutics' Cash from Investing Activities stood at $5.0 million in 2022, then crashed by 142.63% to -$2.1 million in 2023, then tumbled by 1732.19% to -$38.8 million in 2024, then increased by 25.84% to -$28.7 million in 2025.
  • Per Business Quant, the three most recent readings for IKT's Cash from Investing Activities are -$28.7 million (Q3 2025), $9.8 million (Q2 2025), and $21.1 million (Q1 2025).